Benitec Biopharma Current Ratio 2014-2021 | BNTC

Benitec Biopharma current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Benitec Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.02B $0.00B 15.05
2021-03-31 $0.01B $0.00B 5.08
2020-12-31 $0.01B $0.00B 18.46
2020-09-30 $0.01B $0.00B 7.91
2020-06-30 $0.01B $0.00B 9.52
2020-03-31 $0.00B 0.00
2019-12-31 $0.02B $0.00B 20.30
2019-09-30 $0.00B 0.00
2017-09-30 $0.02B $0.00B 11.79
2016-09-30 $0.02B $0.00B 21.71
2016-06-30 $0.01B $0.00B 18.81
2016-03-31 $0.02B $0.00B 12.02
2015-12-31 $0.02B $0.00B 27.81
2015-06-30 $0.02B $0.00B 15.31
2014-12-31 $0.03B $0.00B 41.97
2014-06-30 $0.03B $0.00B 36.36
2013-06-30 $0.00B $0.00B 1.54
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.029B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76